Based on the experience with kinase inhibitors for chronic myeloid leukemia [44], the development of sensitive methodologies to monitor the EGFR pool before and during therapy will constitute an important step in advancing the current use of EGFR kinase inhibitors for cancer. Here, EGFR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.